Creative Planning Viking Therapeutics, Inc. Transaction History

Creative Planning

$129 Billion
Q3 2025

A detailed history of Creative Planning transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 22,242 shares of VKTX stock, worth $885,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,242

Previous 18,559 19.84%

Holding current value

$885,231

Previous $491,000 15.68%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$23.09 - $42.09 $85,040 - $155,017	3,683 Added 19.84%	22,242 $568,000
Q2 2025 Aug 08, 2025	SELL	$19.98 - $29.49 $99 - $147	-5 Reduced 0.03%	18,559 $491,000
Q1 2025 May 15, 2025	BUY	$24.15 - $42.89 $132,076 - $234,565	5,469 Added 41.76%	18,564 $448,000
Q4 2024 Feb 14, 2025	SELL	$38.28 - $78.03 $147,760 - $301,195	-3,860 Reduced 22.77%	13,095 $526,000
Q3 2024 Oct 11, 2024	BUY	$49.84 - $70.47 $59,907 - $84,704	1,202 Added 7.63%	16,955 $1.07 Million

Q2 2024 Aug 15, 2024	BUY	$47.39 - $80.2 $72,222 - $122,224	1,524 Added 10.71%	15,753 $835,000
Q1 2024 May 10, 2024	BUY	$17.4 - $94.5 $247,584 - $1.34 Million	14,229 New	14,229 $1.17 Million
Q3 2023 Nov 16, 2023	SELL	$10.92 - $16.0 $44,761 - $65,584	-4,099 Reduced 73.21%	1,500 $16,000
Q2 2023 Jul 21, 2023	BUY	$14.84 - $24.79 $29,116 - $48,637	1,962 Added 53.95%	5,599 $90,000
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $47,979 - $102,905	-5,938 Reduced 62.02%	3,637 $60,000
Q4 2022 Feb 10, 2023	BUY	$2.72 - $9.4 $26,044 - $90,005	9,575 New	9,575 $90,000
Q3 2020 Nov 05, 2020	SELL	$5.73 - $8.11 $131,635 - $186,311	-22,973 Closed	0 $0
Q2 2020 Jul 23, 2020	SELL	$4.35 - $8.08 $85,260 - $158,368	-19,600 Reduced 46.04%	22,973 $166,000
Q1 2020 May 05, 2020	BUY	$3.45 - $7.95 $10,350 - $23,850	3,000 Added 7.58%	42,573 $199,000
Q4 2019 Jan 30, 2020	SELL	$6.38 - $8.73 $32,538 - $44,523	-5,100 Reduced 11.42%	39,573 $317,000
Q3 2019 Nov 01, 2019	BUY	$6.55 - $8.6 $29,874 - $39,224	4,561 Added 11.37%	44,673 $307,000
Q2 2019 Jul 26, 2019	BUY	$7.67 - $10.63 $7,762 - $10,757	1,012 Added 2.59%	40,112 $333,000
Q1 2019 Apr 24, 2019	BUY	$7.58 - $9.94 $49,270 - $64,610	6,500 Added 19.94%	39,100 $389,000
Q4 2018 Feb 01, 2019	BUY	$7.16 - $16.21 $233,416 - $528,446	32,600 New	32,600 $249,000
Q2 2018 Jul 20, 2018	SELL	$3.88 - $12.74 $341,983 - $1.12 Million	-88,140 Closed	0 $0
Q1 2018 Apr 18, 2018	BUY	$4.11 - $6.93 $74,555 - $125,710	18,140 Added 25.91%	88,140 $385,000
Q4 2017 Jan 17, 2018	BUY	$1.74 - $4.34 $104,400 - $260,400	60,000 Added 600.0%	70,000 $284,000
Q3 2017 Oct 17, 2017	BUY	$0.94 - $1.91 $9,400 - $19,100	10,000	10,000 $19,000

Others Institutions Holding VKTX

# of Institutions

433

Shares Held

66.6M

Call Options Held

7.21M

Put Options Held

3.87M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Viking Therapeutics, Inc. Transaction History